SPDR Series Trust - SPDR S&P Biotech ETF XBI

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index (S&P TMI).

ARCA:XBI - Post by User

SPDR Series Trust - SPDR S&P Biotech ETF

<< Previous

Bullboard Posts

Next >>

(0)
•••

Post by GwenTracyon Jun 03, 2022 5:21am

99 Views

Post# 34728767

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance

FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.

<< Previous

Bullboard Posts

Next >>

Almonty Industries - Value drivers: NASDAQ listing and takeover candidate